Abstract
Background Botulinum toxin type A (BTX-A) has been used for prophylactic treatment in chronic migraine. However, the precise mechanism of its action is obscure. We previously reported that the injection of BTX-A into the facial ophthalmic nerve region reduced the number of the TRPV1-immunoreactve (IR) neurons in the trigeminal ganglion (TG). The dura mater, known as an important site of headache generation, is densely innervated by trigeminal nociceptors. We have recently demonstrated the existence of TRPV1-IR nerve fibers in the dura mater that originate in TG. In this study, we explored the effect of BTX-A on the number of the TRPV1-IR TG neurons innervating the dura mater.
Highlights
Botulinum toxin type A (BTX-A) has been used for prophylactic treatment in chronic migraine
The effects of botulinum toxin type A on the trigeminal TRPV1 containing neurons innervating the dura mater of rat
We previously reported that the injection of BTX-A into the facial ophthalmic nerve region reduced the number of the TRPV1-immunoreactve (IR) neurons in the trigeminal ganglion (TG)
Summary
Botulinum toxin type A (BTX-A) has been used for prophylactic treatment in chronic migraine. The precise mechanism of its action is obscure. We previously reported that the injection of BTX-A into the facial ophthalmic nerve region reduced the number of the TRPV1-immunoreactve (IR) neurons in the trigeminal ganglion (TG). The dura mater, known as an important site of headache generation, is densely innervated by trigeminal nociceptors. We have recently demonstrated the existence of TRPV1-IR nerve fibers in the dura mater that originate in TG. We explored the effect of BTX-A on the number of the TRPV1-IR TG neurons innervating the dura mater. 3 animals), and this was significantly decreased compared to the control group (Student’s t-test, p < 0.0001)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have